Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate

Patricia Ault, Jorge Cortes, Charles Koller, Elizabeth S. Kaled, Hagop Kantarjian

Research output: Contribution to journalArticlepeer-review

125 Scopus citations


Idiopathic hypereosinophilic syndrome (HES) is a rare hematologic disorder characterized by persistent eosinophilia with organ involvement. Patients with HES have a poor prognosis, but the disease course can be heterogeneous. Treatment of HES has included corticosteroids, chemotherapeutic agents such as cyclophosphamide, vincristine, hydroxyrea, and most recently interferon-α (IFN-α) which has shown long-term beneficial effects. We herein report on a patient with HES who had disease resistant to steroids, and chemotherapy with 2-chlorodeoxyadenosine and cytarabine, but who had a significant response after only 8 days of treatment with imatinib mesylate 100mg daily. The possible mechanism of response is discussed. This observation may lead to a better understanding of the pathophysiology of HES, and may provide a new form of effective therapy for the disease.

Original languageEnglish (US)
Pages (from-to)881-884
Number of pages4
JournalLeukemia Research
Issue number9
StatePublished - 2002
Externally publishedYes


  • Hypereosinophilic syndrome
  • Imatinib mesylate

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate'. Together they form a unique fingerprint.

Cite this